Kenneth Borow MD

Dr. Borow is a highly experienced clinician, clinical investigator and trialist, and businessman. He is a Harvard-trained adult & pediatric cardiologist, internist, and pediatrician. As a faculty member at Harvard Medical School and then Professor of Medicine/Pediatrics at the Univ. of Chicago, he authored >100 publications across an array of therapeutic areas. He also oversaw a large multinational research group focused on atherosclerosis and heart failure (HF). Dr. Borow was a senior member of the NHLBI Task Force on HF (chaired by Dr. E. Braunwald). The subsequent report helped establish funding priorities for HF research in the 21st Century.

Dr. Borow’s biopharma experience includes responsibility for Clinical Research Operations in the U.S. & Puerto Rico for Merck Research Labs where he was actively involved in clinical trials for >200 different protocols across 38 drugs. Beginning in 2000, Dr. Borow became President/CEO of a NASDAQ traded multinational CRO with operations in >30 countries. In this role, he helped design and conduct >60 large clinical trials including Pfizer’s landmark REVERSAL and CAMELOT studies, Mylan’s FDA-approved nebivolol development program, and Portola’s Factor Xa inhibitor anticoagulant program.

In 2008, he founded Borrow Consulting Group which focuses on biopharma strategic design, clinical development, and global healthcare processes/analytics for drugs/biologics including stem cells and gene therapy. He has had broad exposure to FDA & EMA. He is also a senior advisor to multiple biopharma companies and numerous prominent VC firms. He holds an array of patents relating to drugs, biologics, and diagnostics. Dr. Borow is also President/CMO of MediMergent, LLC, a public-private partnership with the FDA that is establishing a paradigm-shifting approach to the integration of clinical data acquired from the “Voice-of-the-Patient” and EMRs for assessments of safety, clinical outcomes, drug adherence, and comparative effectiveness.